GAMMADELTA THERAPEUTICS LTD

Company number 10238425

Date	Type	Description	View / Download
26 Jul 2019	RESOLUTIONS	Resolutions RES09 ‐ Resolution of authority to purchase a number of shares RES01 ‐ Resolution of alteration of Articles of Association	(54 pages)
23 Jul 2019	SH06	Cancellation of shares. Statement of capital on 5 July 2019 GBP 6,604.279	(5 pages)
23 Jul 2019	SH03	Purchase of own shares.	(3 pages)
18 Jul 2019	AD01	Registered office address changed from London Bioscience Innovation Centre 2 Royal College Street London NW1 0NH United Kingdom to Westworks 195 Wood Lane White City Place London W12 7FQ on 18 July 2019	(2 pages)
25 Jun 2019	CS01	Confirmation statement made on 16 June 2019 with updates	(7 pages)
18 Apr 2019	SH01	Statement of capital following an allotment of shares on 29 March 2019 GBP 6,604.829	(5 pages)
09 Aug 2018	AA	Accounts for a small company made up to 31 March 2018	(16 pages)
04 Jul 2018	CS01	16/06/18 Statement of Capital gbp 5534.373	(8 pages)
22 Jun 2018	SH01	Statement of capital following an allotment of shares on 31 May 2018 GBP 5,534.373	(4 pages)
08 Feb 2018	SH01	Statement of capital following an allotment of shares on 1 December 2017 GBP 5,465.113	(5 pages)
08 Feb 2018	SH01	Statement of capital following an allotment of shares on 20 December 2017 GBP 5,523.713	(5 pages)
08 Feb 2018	SH01	Statement of capital following an allotment of shares on 18 January 2018 GBP 5,523.713	(5 pages)
06 Oct 2017	AA	Accounts for a small company made up to 31 March 2017	(12 pages)
13 Sep 2017	PSC02	Notification of Abingworth Bioventures Vi Gp Lp as a person with significant control on 24 July 2017	(4 pages)
13 Sep 2017	PSC07	Cessation of Abingworth Llp as a person with significant control on 24 July 2017	(2 pages)
28 Jul 2017	AA01	Previous accounting period shortened from 30 June 2017 to 31 March 2017	(1 page)
18 Jul 2017	PSC02	Notification of Takeda Pharmaceutical Company Limited as a person with significant control on 8 May 2017	(4 pages)
18 Jul 2017	PSC02	Notification of Abingworth Llp as a person with significant control on 15 August 2016	(4 pages)
18 Jul 2017	CS01	Confirmation statement made on 16 June 2017 with updates	(12 pages)
18 Jun 2017	TM01	Termination of appointment of Stephen Barry Parker as a director on 9 June 2017	(2 pages)
31 May 2017	SH01	Statement of capital following an allotment of shares on 8 May 2017 GBP 5,140.113	(4 pages)
25 May 2017	AP01	Appointment of Daniel Matthew Kemp as a director on 8 May 2017	(3 pages)
25 May 2017	RESOLUTIONS	Resolutions RES01 ‐ Resolution of adoption of Articles of Association	(53 pages)
11 May 2017	MR01	Registration of charge 102384250001, created on 8 May 2017	(6 pages)
27 Apr 2017	AD01	Registered office address changed from 38 Jermyn Street London SW1Y 6DN United Kingdom to London Bioscience Innovation Centre 2 Royal College Street London NW1 0NH on 27 April 2017	(2 pages)